Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity.
about
Side effects with amiodarone therapyA Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled studyAmiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha.Amiodarone-induced lung toxicity. In vitro evidence for the direct toxicity of the drug.Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring.Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stressModulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodaroneAmiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicityRoles of the hemostatic system and neutrophils in liver injury from co-exposure to amiodarone and lipopolysaccharide.Examining the safety of amiodarone.Amiodarone-induced pulmonary toxicity--a fatal case report and literature review.Long-term efficacy and toxicity of high- and low-dose amiodarone regimens.Adverse effects of amiodarone. Pathogenesis, incidence and management.Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.A consensus report on antiarrhythmic drug use.Pulmonary complications after long term amiodarone treatment.Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.Acute necrotising myopathy associated with amiodarone therapy.Therapeutic drug monitoring: antiarrhythmic drugsAmiodarone pulmonary toxicity.Effects of chronic oral amiodarone on left ventricular function, ECGs, serum chemistries, and exercise tolerance in healthy dogs.Comparison of plasma concentrations for two amiodarone products.Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs.Response of rat lungs to amiodarone: preferential accumulation of amiodarone and desethylamiodarone in alveolar macrophages.Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation?Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1.Hepatopathy in 4 dogs treated with amiodarone.Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation.Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone.Effect of phenytoin on the clinical pharmacokinetics of amiodarone.Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats.High-resolution sub-cellular imaging by correlative NanoSIMS and electron microscopy of amiodarone internalisation by lung macrophages as evidence for drug-induced phospholipidosis.
P2860
Q28369029-EBAE3E4F-D1C5-4E9B-981A-B7EB0053E732Q30985909-A3077B0E-5324-4983-8CB7-6C0126FE4BB7Q35567061-7DBFD812-1DC3-47ED-829F-E697D0720EFDQ35626791-43D7C789-1B4F-4655-9711-2E78586F1BC3Q35835289-4B491180-959D-4198-AF74-EEDF645C5015Q36013775-EFF26C6E-5ABE-44DE-84BE-D928BA614B8EQ36509054-AD646B5D-1AC6-42A9-9FC2-017385577A93Q37070963-6E38D679-CCCB-4403-AF6E-0C1F9849E046Q37201673-1647F319-D33B-4E59-B4C8-D60A27AE3AA8Q37312627-A90C1770-8C27-493C-A758-9DBE415C664FQ37983124-D339579B-AFDF-48D4-B6E7-C05947A4628DQ38080472-962770BB-385D-4A27-A4EA-C524DA5900B9Q38652012-CD07E064-1C8E-4EB8-90E0-E22350BF2EF7Q38682721-623E9C88-0482-4BB7-961D-74440A87254AQ39578297-54E80DD3-DD1B-4D41-B66A-5B6642281318Q40745450-0D6EF52A-2781-4DE9-8248-2C8E9C44EF6BQ41146146-5AFE7D37-2B0C-4F77-9D0C-7844E91951A5Q41610920-01A2026B-FCB6-4CE3-BE6E-C1D81A01D5D2Q42191837-FE247863-5024-4D4C-91FB-0CEF44740E5CQ42780616-40EF5F0F-309B-489B-90AC-D185014E91DDQ42936697-111D279F-FAD8-4233-A878-20B8D8B71F79Q44012774-66B14B01-9F10-4619-A72C-26C639473B07Q44193210-877D20EC-E0F3-4999-97D6-1A43390FE84DQ44531864-DD410349-2A67-4991-948D-E58C32B5ED75Q44959285-5EA3D379-F6C2-412C-B994-DB6AEF193F7FQ45080745-6AD1CD60-54C2-4898-9429-B5D0280B66DBQ46608132-E8989BCC-2213-4F0D-BA99-55F791035185Q48732011-35C9B47A-1B89-4071-8106-89E3918F2770Q49045361-D14F373C-C672-4CCE-BC53-CA21C9D3EACFQ50762800-D881468C-C202-4D8D-B290-BD22AE6E6976Q52423481-B3703BE1-F598-43E4-A935-3DAB1094F6FBQ52428771-9DD1CD76-1D99-4829-BF5D-15EC7CB15FF9Q52927052-7E41E401-DE58-49A1-B8FE-4250EC64E62F
P2860
Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@en
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@nl
type
label
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@en
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@nl
prefLabel
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@en
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@nl
P2093
P1476
Steady-state serum amiodarone ...... hythmic efficacy and toxicity.
@en
P2093
Belhassen B
Greenspan AM
Greenspon AJ
Horowitz LN
Rotmensch HH
Shoshani D
Spielman SR
Swanson BN
Vlasses PH
P304
P356
10.7326/0003-4819-101-4-462
P407
P577
1984-10-01T00:00:00Z